Esketamine Response in Treatment-Resistant Depression: Pilot Study Data

32 patients with treatment-resistant depression received intranasal esketamine over 2 months in a real-world cohort study. Michaela Krivosova published this data on figshare in 2026 to evaluate the impact of pharmacogenetic, clinical, and demographic variables on antidepressant response. Adjunctive psychotherapy emerged as the only factor significantly associated with remission.

Use Cases

• Analyze associations between remission rates and adjunctive psychotherapy based on the study's findings.
• Explore potential links between metabolic phenotype (CYP2B6, CYP2C9, CYP3A4) and treatment response variability.
• Investigate the impact of concomitant pharmacotherapy on inter-individual differences in esketamine outcomes.
• Model treatment response in relation to genetic variables like BDNF (rs6265) and OPRM1 (rs1799971) polymorphisms.

Strengths

• Data includes pharmacogenetic testing results for 32 patients.
• Depressive symptoms were assessed at baseline and across 12 treatment sessions.
• Published under a CC-BY-4.0 license, allowing for reuse and redistribution.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 32-patient sample size may be underpowered to detect modest associations, as noted in the study.

Provenance

Source

Michaela Krivosova

Collection Method

Real-world cohort study of 32 TRD patients receiving intranasal esketamine.

Freshness

Last updated 2026-05-05 13:23:25; freshness should be verified.